Braveheart Bio (NASDAQ:BRVE) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Braveheart Bio (NASDAQ:BRVE) in a research note issued on Monday, MarketBeat.com reports. The firm set an “overweight” rating and a $40.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 45.77% from the stock’s previous close.

Several other research firms have also recently weighed in on BRVE. The Goldman Sachs Group assumed coverage on Braveheart Bio in a research report on Monday. They issued a “buy” rating and a $48.00 price objective on the stock. Wall Street Zen upgraded Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Jefferies Financial Group assumed coverage on shares of Braveheart Bio in a research report on Monday. They set a “buy” rating and a $48.00 price target for the company. Finally, TD Cowen began coverage on shares of Braveheart Bio in a report on Monday. They set a “buy” rating for the company. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $45.25.

Braveheart Bio Stock Performance

BRVE stock opened at $27.44 on Monday. Braveheart Bio has a 12-month low of $24.61 and a 12-month high of $32.00.

Insiders Place Their Bets

In other news, major shareholder Bio Fund Iv L.P. Ah purchased 1,100,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $18.00 per share, for a total transaction of $19,800,000.00. Following the purchase, the insider owned 10,232,420 shares of the company’s stock, valued at $184,183,560. The trade was a 12.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc acquired 1,940,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the acquisition, the director owned 11,901,826 shares in the company, valued at $214,232,868. The trade was a 19.47% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 8,751,942 shares of company stock valued at $157,534,956 in the last quarter.

About Braveheart Bio

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.